Citigroup Inc Exscientia PLC Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Exscientia PLC stock. As of the latest transaction made, Citigroup Inc holds 4,417 shares of EXAI stock, worth $21,378. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,417

Previous 13,916 68.26%

Holding current value

$21,378

Previous $70,000 70.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.26 - $6.0 $40,465 - $56,994	-9,499 Reduced 68.26%	4,417 $21,000
Q2 2024 Aug 12, 2024	BUY	$3.99 - $6.04 $3,826 - $5,792	959 Added 7.4%	13,916 $70,000
Q1 2024 May 10, 2024	BUY	$5.3 - $7.51 $39,092 - $55,393	7,376 Added 132.16%	12,957 $74,000
Q4 2023 Feb 09, 2024	BUY	$4.35 - $6.88 $643 - $1,018	148 Added 2.72%	5,581 $35,000
Q3 2023 Nov 09, 2023	SELL	$4.52 - $8.9 $2,110 - $4,156	-467 Reduced 7.92%	5,433 $24,000
Q2 2023 Aug 10, 2023	SELL	$4.79 - $8.3 $2.75 Million - $4.77 Million	-574,334 Reduced 98.98%	5,900 $34,000
Q1 2023 May 11, 2023	BUY	$5.3 - $10.93 $3.01 Million - $6.21 Million	568,324 Added 4771.82%	580,234 $3.08 Million
Q4 2022 Feb 09, 2023	BUY	$4.1 - $8.94 $27,342 - $59,620	6,669 Added 127.25%	11,910 $63,000
Q3 2022 Nov 10, 2022	SELL	$7.27 - $12.92 $2,653 - $4,715	-365 Reduced 6.51%	5,241 $43,000
Q2 2022 Aug 10, 2022	SELL	$6.92 - $15.97 $47,921 - $110,592	-6,925 Reduced 55.26%	5,606 $61,000
Q1 2022 May 12, 2022	SELL	$11.52 - $22.05 $29,456 - $56,381	-2,557 Reduced 16.95%	12,531 $180,000
Q4 2021 Feb 10, 2022	BUY	$17.63 - $27.1 $266,001 - $408,884	15,088 New	15,088 $298,000

Others Institutions Holding EXAI

# of Institutions

Shares Held

33.4M

Call Options Held

500

Put Options Held

189K

View Full List

About Exscientia plc

Ticker EXAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,461,000
Market Cap $593M
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...

More about EXAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account